“With an increasing number of drugs being stored in prefillable glass syringes – from GLP-1 drugs to critical vaccines and innovative biologics, the manufacturing beginning at this site today will continue to support major trends in the pharma industry.” Andreas Reisse, CEO, SCHOTT Pharma
After breaking ground in October 2022 and fresh of its IPO in September 2023, SCHOTT Pharma opened the doors to an entirely new production facility for high-quality prefillable glass syringes in Hungary. Supported by a EUR 9 million (HUF 3,321 billion) investment from the local government, SCHOTT Pharma’s double-digit million Euro investment is realized today with the opening of a facility that creates over 120 jobs. With this move, SCHOTT Pharma is expanding its global capacities for strategically important high-value solutions that address key pharma trends. At the same time, the company is strengthening its competitiveness in Europe and the supply security for major pharmaceutical companies and contract manufacturing organizations. To supply the fast and dynamically growing market, SCHOTT Pharma plans to further invest a multi-million Euro amount in Hungary in prefillable syringes in the next years.
“With an increasing number of drugs being stored in prefillable glass syringes – from GLP-1 drugs to critical vaccines and innovative biologics, the manufacturing beginning at this site today will continue to support major trends in the pharma industry,” said Andreas Reisse, CEO of SCHOTT Pharma.
As evidenced by their growing demand in the healthcare industry, these high-quality prefillable glass syringes not only offer a stable, long-term storage solution for drugs, but also a safe and convenient delivery system for patients and clinicians.
Drug containment and delivery play a critical role in medication protocols. Traditionally, a newly developed drug is launched in vials, with healthcare providers using disposable syringes for extraction and administration. Today, more and more pharmaceutical companies are moving towards filling medicines directly into prefillable syringes to enable storage and administration in one, streamlining the injection process for healthcare professionals and improving the accuracy of dosing for patients.
SCHOTT Pharma’s Hungarian site, that was inaugurated in Lukácsháza, builds on the company’s existing foundation and pharmaceutical production skillset in the area, which already plays an important role in supplying the global industry with drug containment systems today. Following the high-end processes and advanced quality assurance found in SCHOTT Pharma’s global production network in 14 countries, the facility is equipped with state-of-the-art machinery. The new site is the second site where the company manufactures glass syringes, in addition to the site in St. Gallen in Switzerland.
